Duke University

Revisiting patient diversity in clinical trials… again

Saturday, July 1, 2017

Minority groups have historically been excluded from clinical research, an inequity that has led to well-documented public health problems in which therapies tested primarily in Caucasian patients do not work as well in other ethnic and racial groups. This problem is famously exemplified by Sanofi’s blood thinner Plavix, which was approved in 1997 but slapped with a boxed warning in 2010 after researchers realized up to half of Asian and Pacific Islander populations cannot process the drug.

[Read More]

bluebird bio, Duke collaborate on value-based payment framework for gene therapy

Tuesday, May 23, 2017

bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that it will participate in a consortium led by Duke University’s Robert J. Margolis, M.D., Center for Health Policy to develop a broadly-supported path for value-based payment reform models for gene therapies and other innovative treatments.

[Read More]

Envisioning the site of the future

Monday, May 1, 2017

The drug development world has been notoriously slow to adopt change, but industry leaders and visionaries expect the clinical research enterprise to change dramatically.
Integration of healthcare data, the power of data and analytics, a rapid move toward more targeted therapies and customized treatments, along with the desire for a lower cost R&D model are among the forces driving transformation in the way the research environment will function in the future.

[Read More]

Verily, Duke and Stanford launch Project Baseline study

Thursday, April 20, 2017

Verily Life Sciences, an Alphabet company, in partnership with Duke University School of Medicine and Stanford Medicine, announced the initiation of the Project Baseline study, a longitudinal study that will collect broad phenotypic health data from approximately 10,000 participants, who will each be followed over the course of at least four years. The study is the first initiative of Project Baseline, a broader effort designed to develop a well-defined reference, or “baseline,” of health as well as a rich data platform that may be used to better understand the transition from health to disease and identify additional risk factors for disease. Beyond this initial study, Project Baseline endeavors to test and develop new tools and technologies to access, organize and activate health information.

[Read More]